Related Experiment Video
Updated: Jun 6, 2025
Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System
Published on: April 11, 2018
Commissioning of a commercial treatment planning system for scanned carbon-ion radiotherapy
Wei Sun1,2, Weiwei Wang1,2,3, Zhijie Huang1,2
1Department of Medical Physics, Shanghai Proton and Heavy Ion Center, Shanghai Key Laboratory of Radiation Oncology, Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China.
Purpose:
To commission the RayStation (RS) TPS (treatment planning system) for scanned CIRT (carbon-ion radiotherapy) utilizing pencil beam algorithms (PBv4.2).
Methods:
The beam model commissioning entailed employing 1D single beams and 2D monoenergetic fields to validate spot profiles with films, assess beam range using Peakfinder measurements, and evaluate fragment spectra through dose-averaged linear energy transfer (LETd) calculations. 3D dose distributions were verified in homogeneous phantoms for both absorbed and relative biological effectiveness (RBE)-weighted doses, and further assessed in double wedge and anthropomorphic phantoms for absorbed dose only. Finally, RBE-weighted dose verification and patient-specific quality assurance were conducted using 58 beams from 20 clinically treated patient plans.
Results:
The results demonstrated good agreement in absolute dose distribution between TPS calculations and measurements, with mean dose discrepancies within 3%. However, deviations were slightly higher (> 1%) for the cases involving the range shifter (RaShi) compared to those without the RaShi (< 1%). Beam range, depth dose distribution, and lateral profiles of spread-out Bragg peaks (SOBPs) closely matched between RS TPS calculations and measurements. Some discrepancies (less than 0.5 mm) were observed at field edges and in penumbra regions due to limitations in simulating asymmetrical spots, but within clinical tolerance. After model tuning, RBE-weighted dose calculations in RS TPS were in agreement with those from the clinically used TPS, except for variations exceeding 3% observed at energies exceeding 408.07 MeV/u, primarily attributed to fragment spectra differences.
Conclusion:
Overall, this study validated the RS TPS for calculating absorbed doses against measurements and RBE-weighted doses against a clinically used TPS. The results suggested that the RS TPS could be utilized for CIRT treatment planning, except for energies exceeding 408.07 MeV/u.
More Related Videos
05:18Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant
Published on: October 6, 2023
07:57Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
Published on: March 24, 2022
